Table 2.
Parameter | Unadjusted Prevalence ratio (95% CI), P value | Fully adjusted Prevalence ratio (95% CI), P value |
---|---|---|
ADMA (per 0.1 μmol/l increase) | 1.19 (1.01, 1.42), P =0.043 | 1.13 (0.94, 1.35), P =0.20 |
Age (per decade) | 1.11 (0.92, 1.33), P =0.28 | 1.13 (0.92, 1.38), P =0.25 |
Female vs. male | 1.36 (0.90, 2.1), P =0.15 | 1.10 (0.68, 1.78), P =0.69 |
African–American vs. white | 1.40 (0.96, 2.1), P =0.080 | 1.24 (0.80, 1.91), P =0.33 |
Other/Latino vs. white | 1.24 (0.75, 2.0), P =0.40 | 1.23 (0.73, 2.1), P =0.44 |
IVDU (current vs. never) | 1.85 (1.09, 3.1), P =0.022 | 1.48 (0.73, 3.0), P =0.28 |
IVDU (past vs. never) | 1.33 (0.91, 1.96), P =0.15 | 1.31 (0.81, 2.1), P =0.27 |
Cigarette smoking (current vs. never) | 1.39 (0.92, 2.1), P =0.11 | 1.06 (0.65, 1.73), P =0.80 |
Cigarette smoking (past vs. never) | 1.04 (0.66, 1.64), P =0.87 | 0.99 (0.61, 1.62), P =0.98 |
Stimulant use (current vs. never) | 1.36 (0.86, 2.1), P =0.19 | 0.97 (0.53, 1.80), P =0.93 |
Stimulant use (past vs. never) | 0.99 (0.66, 1.47), P =0.95 | 0.77 (0.48, 1.24), P =0.28 |
hsCRP (per doubling) | 1.05 (0.95, 1.15), P =0.32 | 1.01 (0.91, 1.12), P =0.91 |
D-dimer (per doubling) | 1.14 (1.00, 1.30), P =0.044 | 1.04 (0.89, 1.22), P =0.60 |
IL-6 (per doubling) | 1.19 (1.05, 1.34), P =0.0057 | 1.10 (0.95, 1.29), P =0.20 |
Analysis includes all 214 HIV-infected participants; prevalence of outcome was 59.8% (128 of 214 participants). Multiple imputation was used to handle missing covariates: CRP (N =181), D-dimer (N =170), and IL-6 (N =164). ADMA, asymmetric dimethylarginine; CI, confidence interval; IVDU, intravenous drug use; PASP, pulmonary artery systolic pressure; PR, prevalence ratio.